SNCA and Parkinson disease: Indatraline-conjugated ASOs (IND-ASO) designed to inhibit α-synuclein selectively reduced α-synuclein accumulation in monoamine neurons in a PD-like mouse model and elderly nonhuman primates after ICV or intranasal administration (Alarcón-Arís et al., 2020).